Prevalence of concomitant medications in older HIV+ patients and comparison with general population [0.03%]
老年HIV感染患者合并用药的普遍性及其与一般人群的比较
Mercedes Gimeno-Gracia,María José Crusells-Canales,Francisco Javier Armesto-Gómez et al.
Mercedes Gimeno-Gracia et al.
Objective: The increasing population of human immunodeficiency virus (HIV)-infected elderly patients results in a higher number of comorbidities and greater incidence of polypharmacy in addition to antiretroviral therapy ...
Comparative Study
HIV clinical trials. 2015 May-Jun;16(3):117-24. DOI:10.1179/1528433614Z.0000000012 2015
Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study [0.03%]
乙型肝炎C病毒治疗后人类免疫缺陷病毒/乙型肝炎C病毒感染患者的生活质量、卫生服务使用和物质使用的改变：前瞻性队列研究
Man Wah Yeung,Jim Young,Erica Moodie et al.
Man Wah Yeung et al.
Objective: Clinical benefits of achieving a sustained virologic response (SVR) with hepatitis c virus (HCV) therapy beyond reducing liver-related outcomes have not been documented in HIV-coinfected patients, who have mult...
Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents [0.03%]
玛巴洛沙韦与对照组联合抗逆转录病毒药物对HIV-1和丙型肝炎以及/或者乙型肝炎病毒感染者的肝脏安全性：一项随机双盲研究
Juergen K Rockstroh,Vicente Soriano,Frank Plonski et al.
Juergen K Rockstroh et al.
Background: One of the more clinically relevant co-morbidities in HIV-infected patients is the development of progressive liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV). In addition, hepatotoxicit...
Randomized Controlled Trial
HIV clinical trials. 2015 Mar-Apr;16(2):72-80. DOI:10.1179/1528433614Z.0000000011 2015
Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain [0.03%]
西班牙抗逆转录病毒治疗的艾滋病毒感染者的心血管风险因素及终生风险评估
Vicente Estrada,José Ignacio Bernardino,Mar Masiá et al.
Vicente Estrada et al.
Background and objectives: Cardiovascular disease is a major concern in HIV-infected patients. Lifetime risk estimations use the risk of developing it over the course of remaining lifetime, and are useful in communicating...
Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety [0.03%]
雷公藤钩吻提取物改善不良免疫应答的HIV感染者CD4 T细胞恢复：一项探索性研究评估其免疫调节作用及安全性
Taisheng Li,Jing Xie,Yijia Li et al.
Taisheng Li et al.
Background: Despite combination antiretroviral therapy (cART), 20% of HIV-infected patients are unable to achieve adequate immunologic recovery, in which immune activation plays a crucial role. We hypothesize that extract...
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls [0.03%]
围产期HIV感染的年轻成人及其未感染HIV兄弟姐妹的大脑功能
Jane Ashby,Caroline Foster,Lucy Garvey et al.
Jane Ashby et al.
Background: Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC fu...
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study [0.03%]
西班牙TRIP研究：在接受抗逆转录病毒治疗的50岁或以上初治患者中，比其他核苷类似物联合疗法而言，含有替诺福韦/恩曲他滨复方制剂的方案对肾脏安全性的优势
Enric Pedrol,Ana M Caro-Murillo,Manuel A Castaño et al.
Enric Pedrol et al.
Objectives: Our aim is to describe the impact of emtricitabine (FTC)/tenofovir (TDF) versus other nucleoside reverse transcriptase inhibitor (NRTIs)-based regimens on renal function of human immunodeficiency virus (HIV) n...
Comparative Study
HIV clinical trials. 2015 Jan-Feb;16(1):43-8. DOI:10.1179/1528433614Z.0000000001 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age [0.03%]
拉替拉韦抗逆转录病毒治疗在六十岁以上HIV感染者中的药动学特征分析
Jaime H Vera,Akil Jackson,Laura Dickinson et al.
Jaime H Vera et al.
Background: Antiretroviral safety and efficacy and may differ in older versus younger HIV-infected patients. The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60 y...
96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects [0.03%]
对比恩曲他滨/富马酸替诺福韦酯+利匹韦林与恩曲他滨/富马酸替诺福韦酯+依非韦伦治疗抗病毒药物初治的HIV感染者为期96周的耐药分析（_STAR研究）
Danielle P Porter,Rima Kulkarni,Todd Fralich et al.
Danielle P Porter et al.
Background: STaR (GS-US-264-0110) was a 96-week phase 3b study evaluating the safety and efficacy of two single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir D...
Clinical Trial
HIV clinical trials. 2015 Jan-Feb;16(1):30-8. DOI:10.1179/1528433614Z.0000000009 2015
Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis [0.03%]
恩曲他滨富马酸替诺福韦二吡曱酯治疗HIV感染者：一项 Meta 分析研究
Sheng-Li Li,Peng Xu,Lei Zhang et al.
Sheng-Li Li et al.
Objectives: The aim of this study was to determine the effectiveness and safety of rilpivirine in treatment-naive adults infected with HIV-1. Methods: ...